Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency

被引：22

作者：

Kry, Stephen F. ^{[1
]}

Lye, Jessica ^{[2
,3
]}

Clark, Catharine H. ^{[4
]}

Andratschke, Nicolaus ^{[5
]}

Dimitriadis, Alexis ^{[6
]}

Followill, David ^{[1
]}

Howell, Rebecca ^{[7
]}

Hussein, Mohammad ^{[8
]}

Ishikawa, Masayori ^{[9
]}

Kito, Satoshi ^{[10
]}

Kron, Tomas ^{[11
,12
]}

Lee, Jonny ^{[13
]}

Michalski, Jeff ^{[14
]}

Monti, Angelo Filippo ^{[15
]}

Reynaert, Nick ^{[16
]}

Taylor, Paige ^{[1
]}

Venables, Karen ^{[13
]}

Xiao, Ying ^{[17
]}

Lehmann, Joerg ^{[11
,18
,19
,20
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Imaging & Radiat Oncol Core, Houston, TX 77030 USA

[2] Australian Radiat Protect & Nucl Safety Agcy, Australian Clin Dosimetry Serv, Melbourne, Vic, Australia

[3] Olivia Newton John Canc Res & Wellness Ctr, Melbourne, Vic, Australia

[4] UCL, NIHR Radiotherapy Trials Qual Assurance Grp, Univ Coll London Hosp, Natl Phys Lab, London, England

[5] Univ Zurich, Univ Hosp Zurich, European Org Res & Treatment Canc Radiotherapy Qu, Zurich, Switzerland

[6] IAEA, Dosimetry & Med Radiat Phys Sect, Div Human Hlth, Dept Nucl Sci & Applicat, Vienna, Austria

[7] Univ Texas MD Anderson Canc Ctr, Radiat Dosimetry Serv, Houston, TX 77030 USA

[8] Natl Phys Lab, Teddington, Middx, England

[9] Hokkaido Univ, Japan Clin Oncol Grp, Fac Hlth Sci, Sapporo, Hokkaido, Japan

[10] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Japan Clin Oncol Grp, Dept Radiat Oncol, Tokyo, Japan

[11] Trans Tasman Radiat Oncol Grp TROG, Newcastle, NSW, Australia

[12] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[13] Mt Vernon Canc Ctr, NIHR Radiotherapy Trials Qual Assurance Grp, Northwood, Middx, England

[14] Washington Univ, Sch Med, Imaging & Radiat Oncol Core, St Louis, MO USA

[15] ASST GOM Niguarda Hosp, Dept Med Phys, European Org Res & Treatment Canc EORTC, Milan, Italy

[16] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Phys, European Org Res & Treatment, Brussels, Belgium

[17] Univ Penn, Imaging & Radiat Oncol Core, Philadelphia, PA 19104 USA

[18] Calvary Mater Newcastle, Dept Radiat Oncol, Waratah, Australia

[19] Univ Newcastle, Sch Math & Phys Sci, Callaghan, NSW, Australia

[20] Univ Sydney, Inst Med Phys, Sydney, NSW, Australia

来源：

RADIOTHERAPY AND ONCOLOGY | 2021年 / 159卷

关键词：

Clinical trial; GHG; Radiation dosage; Dose calculation; Dose to medium; Dose to water; HIGH-ENERGY PHOTON; CARLO-BASED PHOTON; CALCULATION ALGORITHMS; WATER; THERAPY; DOSIMETRY; BONE; SPECIFICATION; DIFFERENCE; IMPACT;

D O I：

10.1016/j.radonc.2021.03.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To promote consistency in clinical trials by recommending a uniform framework as it relates to radiation transport and dose calculation in water versus in medium. Methods: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG; www.rtqaharmonization.org) compared the differences between dose to water in water (D-w,D-w), dose to water in medium (D-w,D-m), and dose to medium in medium (D-m,D-m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. Results: No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (D-m,D-m). Conclusions: Dose to medium in medium (D-m,D-m) is the preferred dose calculation and reporting framework. If an institution's planning system can only calculate dose to water in water (D-w,D-w), this is acceptable. (C) 2021 The Authors. Published by Elsevier B.V.

引用

页码：106 / 111

页数：6

共 6 条

[1] Report dose-to-medium in clinical trials; a consensus from the Global Harmonisation Group
Kry, S.
Lye, J.
Clark, C.
Andratschke, N.
Dimitriadis, A.
Followill, D.
Howell, R.
Hussein, M.
Ishikawa, M.
Kito, S.
Kron, T.
Lee, J.
Michalski, J.
Monti, A.
Reynaert, N.
Taylor, P.
Venables, K.
Xiao, Y.
Lehmann, J.
[J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S738 - S739
[2] A Consensus Report from the Global Harmonisation Group On Clinical Trials: Report Dose-To-Medium
Kry, S.
Lye, J.
Clark, C.
Andratschke, N.
Dimitriadis, A.
Followill, D.
Howell, R.
Hussein, M.
Ishikawa, M.
Kito, S.
Kron, T.
Lee, J.
Michalski, J.
Monti, A.
Reynaert, N.
Taylor, P.
Venables, K.
Xiao, Y.
Lehmann, J.
[J]. MEDICAL PHYSICS, 2021, 48 (06)
[3] Consistency of OAR delineation for clinical trials: A Global Harmonization Group Consensus
Mir, R.
Kelly, S.
Xiao, Y.
Moore, A.
Clark, C.
Clementel, E.
Corning, C.
Ebert, M.
Hoskin, P.
Hurkmans, C.
Ishikura, S.
Kristensen, I.
Kry, S.
Lehmann, J.
Michalski, J.
Monti, A.
Nakamura, M.
Thompson, K.
Yang, H.
Zubizarreta, E.
Andratschke, N.
Miles, E.
[J]. RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S682 - S683
[4] Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group
Jasvinder A. Singh
Michael Dohm
Peter F. Choong
[J]. BMC Musculoskeletal Disorders, 18
[5] Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group
Singh, Jasvinder A.
Dohm, Michael
Choong, Peter F.
[J]. BMC MUSCULOSKELETAL DISORDERS, 2017, 18
[6] Toward a Global Consensus on Outcome Measures for Clinical Trials in Tinnitus: Report From the First International Meeting of the COMiT Initiative, November 14, 2014, Amsterdam, The Netherlands
Hall, Deborah A.
Haider, Haula
Kikidis, Dimitris
Mielczarek, Marzena
Mazurek, Birgit
Szczepek, Agnieszka J.
Cederroth, Christopher R.
[J]. TRENDS IN HEARING, 2015, 19

← 1 →